Genetic Modifiers and Oligogenic Inheritance

Maria Kousi and Nicholas Katsanis

Center for Human Disease Modeling, Duke University, Durham, North Carolina 27710

Correspondence: katsanis@cellbio.duke.edu

Despite remarkable progress in the identification of mutations that drive genetic disorders, progress in understanding the effect of genetic background on the penetrance and expressivity of causal alleles has been modest, in part because of the methodological challenges in identifying genetic modifiers. Nonetheless, the progressive discovery of modifier alleles has improved both our interpretative ability and our analytical tools to dissect such phenomena. In this review, we analyze the genetic properties and behaviors of modifiers as derived from studies in patient populations and model organisms and we highlight conceptual and technological tools used to overcome some of the challenges inherent in modifier mapping and cloning. Finally, we discuss how the identification of these modifiers has facilitated the elucidation of biological pathways and holds the potential to improve the clinical predictive value of primary causal mutations and to develop novel drug targets.

Since the mapping of the first locus for autosomal dominant retinitis pigmentosa (RP) on the long arm of chromosome 3 (McWilliam et al. 1989) and the subsequent identification of rhodopsin (*RHO*) as the causal transcript (Dryja et al. 1990), the genetic dissection of disorders in which retinal degeneration comprises a core phenotypic component has accelerated rapidly, leading to the report of more than 250 loci and genes cataloged in RetNet (as of May 2014; see <https://sph.uth.edu/retnet/disease.htm>). These advances have had a clear contribution to both our understanding of photoreceptor biology and in providing genetic diagnoses to families. At the same time, however, post hoc knowledge of disease-causing genes and mutations had a modest impact on the predictive ability of prognosis with regard to key

aspects of disease expressivity, such as age-of-onset, rate of progression, severity, and manifestation of other comorbidities. Numerous reports exist in the literature in which patients with the same primary mutation show stark differences in phenotypic expressivity, with the more striking examples coming from nonidentical twin studies in which patients that grow under a shared environment and carry the same primary mutation display distinct phenotypes, most likely because of genetic determinants that act as modifiers (Walia et al. 2008). The example above is not an isolated oddity. Accumulating clinical and genetic evidence now suggests that, even for classically monogenic disorders, the view that the expressivity of the phenotype is exclusively the property of dominant or recessive mutations at a single locus

Editors: Eric A. Pierce, Richard H. Masland, and Joan W. Miller
Additional Perspectives on Retinal Disorders: Genetic Approaches to Diagnosis and Treatment available at www.perspectivesinmedicine.org

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a017145
Cite this article as *Cold Spring Harb Perspect Med* 2015;5:a017145

M. Kousi and N. Katsanis

might be an oversimplification of the biological phenomena (Dipple and McCabe 2000; Badano and Katsanis 2002; Schäffer 2013).

The concept of modifier genes and alleles is not new (Haldane 1941). Nonetheless, the field of retinal degeneration disorders has been in a unique position to lead the efforts to understand genetic architecture, causality, and variable expressivity. This is in part because of (1) large and well-phenotyped multiethnic cohorts; (2) a substantial (and growing) mutational target of almost 300 genes, each known to be necessary for retinal biogenesis, homeostasis, and/or function; and (3) the availability of in vitro and in vivo tools to model genetic interaction phenomena. Here we will discuss the concepts of modifier genes and alleles, including their evolving terminology; we will highlight examples that illustrate the still episodic, yet significant, advances in dissecting the genetic basis of modification of penetrance and expressivity; and we will discuss possible avenues toward improving our interpretative ability of such events.

PROPERTIES OF GENETIC MODIFIERS

A critical step in understanding genetic modification phenomena consists of providing a clear definition for the term itself. Phenomena described by terms such as epistasis, oligogenic inheritance, or genetic interaction/modification, are all effective synonyms of the same process, namely, the effect of one gene/allele on the phenotypic outcome of a second gene/locus. A distinction that can aid better defining these genetic phenomena consists in establishing whether the primary locus is both necessary and sufficient to cause disease. If yes, then the presence of allele(s) at a second locus/gene exerts purely a modifying role on the severity of the phenotype as defined by the rate of disease progression; the severity of the phenotype with regard to its pleiotropy; or in the manifestation of endophenotypes that necessitate genetic interactions; if not, then the requirement of an allele in a second gene to manifest pathology defines a case of digenic or oligogenic inheritance (Fig. 1). In general, in the context of dis-

secting modifier phenomena, four major parameters play a prominent role:

1. *Allelic heterogeneity.* Phenotypic variability can stem from mutations in different genes that contribute to disease endophenotypes. However, simpler models of genetic heterogeneity and their influence on phenotypic expressivity should first be considered. Locus and allelic heterogeneity are highlighted in Leber congenital amaurosis (LCA), a disorder for which at least 11 causative genes have been reported under a recessive paradigm (reviewed in Davis and Katsanis 2012). In addition to genetic heterogeneity, LCA is also an example of allelic heterogeneity. For example, nonsense and frameshift, as well as missense mutations in *CEP290* drive disorders ranging between nonsyndromic LCA to Joubert syndrome (JBTS) to the more severe Meckel Gruber syndrome (MKS) phenotype. These observations have reasonably suggested that modifier genetic factors account for this marked variance in clinical presentation (den Hollander et al. 2006, 2008; Sayer et al. 2006; Valente et al. 2006; Baala et al. 2007; Frank et al. 2007; Perrault et al. 2007). However, a discrete intronic mutation (c.2991+1655A>G) in *CEP290* that creates a strong splice-donor site and inserts a cryptic exon in the *CEP290* mRNA resulting in an aberrantly spliced transcript, appears to be sufficient to cause LCA (den Hollander et al. 2006, 2008; Sayer et al. 2006; Valente et al. 2006; Baala et al. 2007; Frank et al. 2007; Perrault et al. 2007). These data argue that, at least in some instances, this mutational event alone is sufficient to explain the disease without necessarily evoking the action of additional alleles. In this example, recurrence of the specific mutation has facilitated that argument. However, typically bereft of such data, dissecting phenotype–genotype correlations within a primary causal locus from modifier effects can be challenging, especially because most such correlations are made on the basis of a few mutations.
2. *Multiple interactions and gene/allele-specific interactions.* The effect of genetic modifiers

Genetic Modifiers and Oligogenic Inheritance

Figure 1. Schematic of the effects of modifiers on causal mutations. A genetic modifier can exert its effect on the phenotype established by mutation(s) at the primary locus in a number of ways. Depending on the nature of the modifier, this interaction can result in reduced penetrance of specific endophenotype(s) and/or disorders; in variable expressivity with the modifying locus resulting in either exacerbated phenotypes (i.e., earlier age of onset and faster progression of the disease); in a milder clinical presentation (i.e., later age of onset, attenuated disease progression, and absence/protection from specific endophenotypes); and modifiers that potentiate the manifestation of specific endophenotypes resulting in what is described as novel forms of disease. This figure was prepared using Servier Medical Art (<http://www.servier.com/Powerpoint-image-bank>).

on penetrance and/or expressivity can vary from a “monogenic” model of modification, in which one modifier can account for most of the observed variability, to a more complex model in which more than one genetic determinant interacts with the primary disease locus. Although identification of major or “panmodifiers” is feasible, the dissection of more than one gene modulating the pheno-

type caused by the primary locus is challenging, due primarily to lack of genetic power. An example illustrating the mapping of a “pan-modifier” was described in a Bardet-Biedl syndrome (BBS) cohort of 226 patients not preselected for mutations at any specific locus. Within this group, an allele in *CCDC28B* was associated with a more severe BBS phenotype, a discovery based on association analy-

sis and transmission disequilibrium testing (TDT) and dissected further by biochemical studies (Badano et al. 2006). Had the modifying effect of *CCDC28B* been specific to a particular BBS locus, unmasking of such a genetic interaction would have been difficult. In contrast to “panmodifiers,” the interplay of multiple modifiers, each of which has a variable strength of effect on the final disease expression is probably common, but the most challenging to unravel. A good example is cystic fibrosis, a life-shortening recessive disorder in which 90% of the affected patients die because of obstructive pulmonary disease (Cutting 2010). Despite the majority of patients carrying identical genotypes (homozygosity for *CFTR* F508del), striking differences in lung function have been described (Kerem et al. 1990). Candidate modifier studies reported that functional variants in *MBL2* and alleles in the promoter and first exon of *TGFb1* were associated with lower lung function measures (Garred et al. 1999; Drumm et al. 2005; Darrah et al. 2010). More recently, genome-wide association studies revealed additional modifiers of lung function; *IL-8*, *IFRD1* and *ENDRA* associated with neutrophil function (Vanscoy et al. 2007; Hillian et al. 2008). Taken together, the aforementioned genetic modifiers are believed to alter lung disease severity by affecting the ability of the host to tolerate infection, which can be further modified by nongenetic determinants such as air pollutants, secondhand smoking, or even access to medical care and treatment (Rubin 1990; Goss et al. 2004). Under such a model, each modifier explains only a small portion of the variability, similar to the genetic risk factors involved in complex traits.

3. *Modifiers in the same locus/region with the disease driver.* Genetic modifiers in *cis* with the disease driver gene might be considered to be variants tagging and being transmitted in linkage disequilibrium with the primary mutation. An example of a modifier in *cis* comes from several studies showing that variants within *FTO* were reported to confer susceptibility to developing obesity (Dina

et al. 2007; Frayling et al. 2007; Scuteri et al. 2007; Church et al. 2010). Although *FTO* was shown to regulate body mass, the variants identified appeared to have no effect on the expression and stability of the protein (Klötting et al. 2008; Grunnet et al. 2009). Instead, the variants within the *FTO* region are regulating the expression of a transcription factor located in *cis*, *IRX3* that is now thought to potentially act as the primary susceptibility gene for developing obesity (Smemo et al. 2014). An example of *trans* modification within the same locus was described in a pedigree diagnosed with erythropoietic protoporphyria (EPP), in which the patients carry a splice donor site deletion resulting in skipping of exon 10 (Δ ex10) of ferrochelatase (*FECH*). When this change is accompanied by an in *trans* intragenic variant (IVS3-48C), the phenotype is aggravated with the levels of ferrochelatase in those patients being significantly lower than in asymptomatic carriers (Gouya et al. 1996, 2006). The mechanism underlying this phenomenon consists in IVS3-48C modulating the use of a constitutive aberrant acceptor splice site on *FECH* resulting in an aberrantly spliced mRNA that is subject to nonsense-mediated decay and therefore leading to *FECH* deficiency (Gouya et al. 2002).

4. *Frequency of the modifying variants in the general population.* Assuming that a modifier allele alone is not sufficient to induce pathology, it might be relatively common in the general population, thus complicating the dissection of phenotypically relevant versus benign variants. In the study that identified an allele that confers susceptibility to Hirschsprung disease (HSCR), the causal variant had a minor allele frequency (MAF) of 0.45 in Asia, 0.25 in Europe and was virtually absent (0.01) in the African population (Emison et al. 2005). Unmasking such common variants may require the use of multiple methods; in this case the combinatorial use of careful phenotyping combined with human genetic, comparative genomic, functional, and population genetic analyses

(Emison et al. 2005). At a second tier, there are alleles of intermediate frequency in the general population. An example of this is the p.A229T allele in *RPGRIP1L* which aggravates the retinal phenotype in ciliopathy patients, present in 3% of Northern Europeans (Khanna et al. 2009). Finally, rare variants that are enriched in patients compared with controls can have a modifying effect on disease expressivity and penetrance. In age-related macular degeneration (AMD), in which most primary driver variants are common, rare alleles (MAF < 1%) within the complement pathway can alter the disease phenotype. The first example described the rare p.R1210C mutation in *CFH* as a penetrant allele that confers high risk to AMD and was followed by the discovery of an additional five risk and 15 protective variants through a study that evaluated components of the complement pathway (Raychaudhuri et al. 2011; Seddon et al. 2013). Although it is easier to establish the relevance of a rare variant to disease causality or predisposition, the same is not true for common variants that are overrepresented in the control population. In the context of genetic modification the true debate is not how common or rare a variant is, but rather how those variants work together and what is their cumulative effect (Gibson 2012).

CHALLENGES IN IDENTIFYING MODIFIER GENES/ALLELES

In contrast to the remarkable progress in identification of disease causing genes, the dissection of oligogenic and epistatic phenomena is lagging, in part because of the reduced power of traditional genetic analyses to uncover such phenomena. Beyond methodological limitations, there are additional challenges to consider:

1. *Availability of accurate clinical evaluation and longitudinal studies.* The identification of genetic modifying phenomena relies heavily on the detailed characterization of the aspect(s) of the phenotype under modification. It

Genetic Modifiers and Oligogenic Inheritance

is thus imperative to have detailed clinical longitudinal information. Historically, cohorts have been characterized qualitatively for the presence/absence of a trait (i.e., RP or macular degeneration), with since-point proxies used as an imperfect means of expressing disease progression; these have included age of onset of a specific phenotype (Badano et al. 2006), thickness of the outer nuclear layer (ONL) (Danciger et al. 2008), or number of photoreceptors (Haider et al. 2008). The literature however, is populated by incomplete phenotypic information on the cases presented, often focusing on specific aspects of disease. In BBS, a multisystemic disorder characterized by rod-cone dystrophy, central obesity, polydactyly, and retinal degeneration, a cardinal symptom of the disorder, renal dysfunction had been overlooked (Brattgard 1949; Landau et al. 1949). A reason for this could have been that, although renal structural abnormalities might be present, only a small fraction of the patients develop symptoms consistent with kidney functional impairment that would prompt clinical evaluation (Magro and Peres 1970; Labrune et al. 1974; Gershoni-Baruch et al. 1992; Beales et al. 1999). In the case of *RPGRIP1L*, thorough description of the retinal phenotype across a cohort of patients with syndromic disorders falling under the umbrella of the ciliopathies, led to the dissection of the p.A229T allele as a variant associated with increased loss of photoreceptors, whereas absence of this change was proposed to have a potential protective effect from RP (Khanna et al. 2009).

2. *Nongenetic factors.* The effect of nongenetic factors poses a major confounder. In humans, one way to determine whether the phenotypic variability observed is caused by genetic modifiers or environmental factors is to compare inter- and intrafamilial variability. A second approach is that of comparing the phenotype in monozygotic (MZ) and dizygotic (DZ) twins that share the same environmental influence. One of the best characterized examples of nongenetic-

M. Kousi and N. Katsanis

ic determinants leading to disease manifestation comes from studies linking pregnancies complicated by fetal neural tube defects (NTDs) with folate insufficiency, and the evidence that periconceptional folate supplementation can reduce the risk of NTDs and other congenital abnormalities (Laurence et al. 1980; Tolarova 1982; Czeizel and Dudás 1992; Wald et al. 2001).

STRATEGIES FOR CLONING GENETIC MODIFIERS

The examples of disease modifier identification existing in the literature have used a plethora of techniques and approaches (Fig. 2), typically combining several lines of investigation:

1. *Linkage analyses.* If nuclear families with individuals carrying the same primary locus mutation and displaying discordant phenotypes are available, linkage analyses to identify alleles identical by descent (IBD) in individuals sharing a specific trait or endophenotype can be performed. The same can be applied in sib pairs concordant or discordant for a given phenotype. Knowing the primary disease causing mutation, linkage analysis for the detection of modifier loci can be performed by evaluating the sample set for qualitative phenotypes (mutation carriers with the phenotype, mutation carriers without the phenotype, and mutation carriers with more severe disease form), or for quantitative phenotypes (i.e., age of onset). One of the reasons that could account for the inability to map modifiers is that, especially in human studies, large pedigrees are often necessary to map the regions harboring the genes of interest. This is exemplified in Fuchs corneal dystrophy (FCD), in which genome-wide linkage in a large multigenerational pedigree carrying the *TCF8* p.Q840P allele that drives disease, revealed a second locus on 9p that, when combined with *TCF8* p.Q840P, results in a more severe form of disease (Riazuddin et al. 2010). Even when large pedigrees are available, variable intra-familial phenotypic expression, in associa-

tion with the difficulty to identify families with uniform phenotypes, can complicate mapping of modifiers. To address this, screening pedigrees from genetic isolates can prove beneficial. Such a study was performed on the Menonite genetic isolate to identify genes underlying HSCR (Carrasquillo et al. 2002). Using a genome-wide association study coupled with multipoint-linkage disequilibrium analysis, which searches for association arising from common mutation ancestry, linkage over known HSCR loci was detected. However, this signal was insufficient to explain disease manifestation (Carrasquillo et al. 2002). Instead, it was an epistatic interaction between the receptor tyrosine kinase (*RET*) and the endothelin receptor type B (*EDNRB*) that was necessary for disease manifestation (Carrasquillo et al. 2002).

2. *Candidate locus association studies.* The advantage of this approach consists mainly in that data from singletons can be compared with other unrelated patients with similar phenotypes. A limitation of this approach is that once association is established, it is difficult to discern whether it is truly owing to the polymorphism/marker identified, to a variant that is in linkage disequilibrium (LD) with the marker used, or to an unknown confounding factor that might not even be genetic (Génin et al. 2008). An alternative is family-based association and TDT, in which the preferential transmission of alleles from parent to affected offspring is evaluated (Spielman et al. 1993). In HSCR, linkage of modifiers has been shown consistently to the *RET* locus, harboring the main HSCR driver, *RET*, although in most of these studies no coding mutations could be identified (Bolk et al. 2000; Borrego et al. 2000; Gabriel et al. 2002; Garcia-Barceló et al. 2003; Sancandi et al. 2003). In these studies, it was hypothesized that the genetic determinant conferring increased susceptibility to HSCR when combined with mutations in other loci, would lie within the *RET* locus (Emison et al. 2005). As such, a combination of human ge-

Figure 2. Examples of strategies for cloning modifiers. **A.** Linkage analysis, with the affected family members manifesting specific endophenotypes or differential disease severity. By evaluating the sample set for the endophenotype or trait of interest, the candidate modifier loci can be mapped. The snapshot of chromosome 9 in panel **A** is from the UCSC browser (<http://genome.ucsc.edu/>). **B.** Association studies compare patient cohorts with (gray figures) or without (white figures) a modifier of disease severity/expressivity, to obtain a signal for the locus/position that harbors the modifying allele(s). **C.** The candidate gene approach evaluates whether genes whose products operate within the same pathway can exert a modifying effect on each other. The example illustrated comes from the observation that mutations in *PRPH2* and *ABCA4* can aggravate disease severity when combined with primary disease mutations in *ROM1*. **D.** The system-based hypothesis evaluates the likelihood of specific genes to physically interact or manifest similar expression profile changes in control versus affected individuals to build genetic networks that drive disease pathogenesis. Such network interactions among genes that cause the same or similar disorders is exemplified by BBS, in which the responsible genes are shown to operate and interact together. **E.** In transcriptome analyses, heatmaps compare changes in expression levels of genes, between healthy and affected individuals. **F.** The use of mouse congenic strains to map modifiers in a more simplified genetic background. This figure was prepared using Servier Medical Art (<http://www.servier.com/> Powerpoint-image-bank).

M. Kousi and N. Katsanis

netic, comparative genomic, functional and population genetic analyses were undertaken to show that the variant sought was an intronic change within a conserved enhancer sequence in intron 1 of *RET* (Emison et al. 2005). A similar approach was used to show the overtransmission of the *CCDC28B* modifier in BBS (Badano et al. 2006).

3. *Candidate gene approach.* One strategy to identify genetic modifiers is by applying a hypothesis-based candidate gene approach through the screening of genes that operate within the same biological pathways/processes as the primary disease driver gene(s). Such hypotheses can be formulated either through current experimental or in silico knowledge of gene networks or from evidence from model organisms. Using this approach, Poloschek and colleagues screened 15 family members for mutations in genes known to cause retinal degeneration. They identified heterozygous mutations in *PRPH2*, *ABCA4*, and *ROM1*; family members carrying the p.R172W mutation in *PRPH2* were severely affected, patients carrying heterozygous alterations in only one of those genes displayed a milder phenotype and patients with heterozygous mutations in all three genes evaluated, show an even more severe form of disease (Poloschek et al. 2010). Another example based on the candidate gene approach involved the identification of the genetic interaction between *NPHP1* and *AHI1*, with *NPHP1* accounting for the nephronophthisis phenotype and the *AHI1* p.R830W allele being the major determinant driving the retinal phenotype in the NPHP cohort (Louie et al. 2010).
4. *System-based candidates.* This approach requires a priori knowledge of the specific genes driving the pathogenesis of the trait of interest. In the human disease network hypothesis, genes associated with similar disorders show higher likelihood of physical interactions and higher expression profiling similarity between their products (Goh et al. 2007). Such an interaction network was constructed for 54 proteins involved in 23

distinct types of human inherited ataxias (Lim et al. 2006). Within this network, different ataxia-causing proteins showed physical interactions and revealed common cellular pathways potentially relevant to disease (Lim et al. 2006). To test the robustness of this approach, the ataxia network was evaluated for its ability to unravel both modifiers and disease drivers. Two major modifiers of spinocerebellar ataxia type 1 (SCA1), ataxin-2 (ATXN2) and RNA binding protein with multiple splicing (RBPMS) were present on the “ataxia-genome” map as nodes that shared strong physical interactions with ataxin-1 (ATXN1) (Lim et al. 2006). BBS represents another example of this approach, with more than 20 causative genes participating in the function of the cilium and thus showing that they are related to each other at a higher level of cellular and organismal organization (Davis and Katsanis 2012). As such, other proteins localizing and operating within the cilium emerge as candidates to either drive disease pathology or modulate phenotypic expressivity. Starting with the bona fide genes that can cause BBS under a recessive paradigm in some families, and thus representing de facto contributors to the molecular etiology of BBS, an excess of pathogenic heterozygous BBS alleles were found in families with recessive mutations in other BBS loci (Katsanis et al. 2001; Badano et al. 2003; Beales et al. 2003; Stoetzel et al. 2006, 2007; Leitch et al. 2008). These phenomena were not restricted to genes mutated in BBS under a recessive paradigm; the BBS modifier *CCDC28B* was screened based on its interaction and colocalization with multiple BBS proteins, in addition to the fact that it was belonging to the ciliary proteome and hence operating in the same system as the other BBS proteins (Li et al. 2004; Badano et al. 2006; Gherman et al. 2006).

5. *Transcriptome analyses.* Methodologies that evaluate the expression of proteins such as microarrays and RNA-seq present powerful tools for studying the transcriptional landscape of a given cell or tissue. Transcrip-

tome analyses compare the expression levels of proteins between different phenotypic groups, such as control versus disease organism. The comparison can be applied to the whole transcriptome of the tissue of interest, or it can be combined with other methodologies such as linkage analyses, to identify only the genes that have altered expression within the locus of interest. Whole transcriptome comparison was performed between four siblings (two of which were asymptomatic) and two unrelated patients affected by spinal muscular atrophy (SMA), all of which carried identical *SMN1/SMN2* genotypes (Oprea et al. 2008). One transcript showing statistically significant differential expression between the individuals with discordant phenotypes was plastin 3 (*PLS3*), a protein that elevates the F actin levels and promotes axonogenesis, comprising the first protective modifier in SMA reported (Oprea et al. 2008). The protective effect of *PLS3* was illustrated further in a conditional mouse model overexpressing *PLS3* into an SMA background (*SMA_{PLS3}*), with the motor neurons of the *SMA_{PLS3}* mice showing restored actin dynamics, increased size of the somata, increased quantal content of the neuromuscular junctions, axon stabilization, increase in the size of innervated muscle fibers, and overall prolonged survival (Ackermann et al. 2013; Lyon et al. 2014).

6. *Considering whole-exome data in toto.* A more unbiased approach to screen for genetic modifiers is through interrogation of the whole exome. Advances in massively parallel sequencing over the past years have made such analyses feasible. The caveat in using such large-scale screens lies in the small sample size available to screen for modifiers, the failure to correct for multiple hypotheses testing when several variants and genetic markers are examined, as well as the effects of population stratification (Gusella and MacDonald 2009). Nonetheless, the advantage of using these technologies consists mainly in the fact that they provide an unbiased approach. This is illustrated by recent

studies in Gordon Holmes syndrome (GHS), a rare form of cerebellar ataxia associated with hypogonadotropic hypogonadism. Analysis of whole-exome sequencing (WES) identified rare alleles in a large consanguineous pedigree and when the genetic findings were coupled to functional studies concluded that, in that family GHS was hypomorphic caused by combinatorial mutations in two independent genes (*RNF216* and *OTUD4*), both of which participate in the ubiquitin proteasome pathway (Margolin et al. 2013). There are several conclusions that can be drawn by this study: (1) if significant linkage was obtained over the locus of one or both of the genes identified, it would have most probably led to the mapping of the one of the genes of this interaction, leaving the second locus unexplored; (2) if the epistatic interaction in GHS had not been underlay by homozygous hits in both genes, but rather was mediated by a homozygous hit in the primary locus and a heterozygous hit in the second or epistatic locus, it would have likely been missed by “typical” WES allele filtering; (3) without the use of the in vivo functional model uncovering the functional synergy of the two genes, *RNF216* would have been proposed as the gene underlying GHS because of identification of mutations in this gene in unrelated patients, leading to the false conclusion that *OTUD4* is not relevant to disease.

7. *Modifiers in inbred and mutation-induced mouse strains.* The most successful approach to map genetic modifiers are mouse models that show phenotypic divergence caused by their different genetic background. A study illustrating the power of this approach to identify genetic modifiers consisted of crossing C57BL/6J-*tub/tub* mice that display retinal and cochlear degeneration (Heckenlively et al. 1995; Ohlemiller et al. 1997) with AKR/J^{-/+} animals. In the F2 generation, the C57BL/6J:AKR/J-*tub/tub* mice were protected from retinal degeneration, having an almost normal ONL thickness and number of photoreceptors when compared with the C57BL/6J-*tub/tub* littermates (Ikeda

M. Kousi and N. Katsanis

et al. 2002a). Subsequent analysis identified significant linkage over the *motr1* locus on chromosome 11 and yielded suggestive evidence for linkage at two loci on chromosomes 2 and 8, respectively (Ikeda et al. 2002a).

GENETIC MODIFIERS OF RETINAL DEGENERATION IN HUMANS

The report of a nuclear family with a 3 bp deletion in peripherin (*RDS*) presenting with three distinct clinical phenotypes (RP, pattern macular dystrophy, and fundus flavimaculatus; Table 1), provided the first example of complex inheritance in retinal degeneration (Weleber et al. 1993). The identification of additional families with *RDS* mutations and significant inter- and intrafamilial variability ensued (Apfelstedt-Sylla et al. 1995). Kajiwarra and colleagues then chose three clinically variable families carrying the heterozygous *RDS* p.L185P allele; the investigators undertook a candidate gene approach and screened for mutations in the gene encoding the retinal outer segment membrane protein 1 (*ROM1*), whose homodimer protein products complex with those encoded by *RDS* (Goldberg and Molday 1996). This study revealed that only family members that were double heterozygotes for the *RDS* p.L185P alleles and the *ROM1* p.114fsX developed RP, whereas individuals that were heterozygous for either one of these mutations did not (Kajiwarra et al. 1994; Rivolta et al. 2002). The mechanism through which such a genetic interaction can affect the clinical phenotype has also been elucidated, revealing that *RDS* mutant subunits fail to homodimerize and that the formation of functional complexes is further decreased by the frameshifting mutation in *ROM1*, thus leading to the ultimate degeneration of photoreceptors in the retina (Goldberg and Molday 1996; Loewen et al. 2001). The effect of *ROM1* as a modifier of phenotype was highlighted further in a study in which cases with heterozygous *ROM1* mutations (p.R172W or p.R229H) combined with mutations in *RDS* result in a more severe phenotype, with pronounced loss in rod but not cone function (Poloschek et al.

2010). In the same study, a subset of patients with mutations in yet a third gene (*ABCA4*: p.R172W, p.R229H or p.V2050L) were present together with *ROM1* and *RDS* mutations; the phenotype was even more severe, with advanced macular degeneration, nyctalopia, and severe rod and cone function decline (Poloschek et al. 2010).

A second modifier of retinal degeneration identified through the candidate gene approach was *AHI1* in a study evaluating patients with nephronophthisis (NPHP), a hereditary kidney disease (Louie et al. 2010; Table 1). More specifically, within a pedigree with three NPHP diagnosed patients, one brother was also carrying the heterozygous *AHI1* p.R830W mutation (Louie et al. 2010). This variant was shown to be associated with retinal degeneration both in this familial case but also among sporadic NPHP patients (Louie et al. 2010), thus attributing a retinal degeneration modifying effect role to *AHI1*. In addition to the NPHP cohort, *AHI1* was also screened for mutations and reported as a genetic modifier in a Belgian cohort of eight *CEP290* mutation positive patients affected by LCA and mental retardation (Coppieters et al. 2010). The patients most severely affected were carriers of *AHI1* p.N811K and p.H758P, leading to the conclusion that *CEP290* and *AHI1* are likely to be operating in the same pathway and that within this cohort *AHI1* serves as a modifier of the neurological phenotype (Coppieters et al. 2010).

A third example came from the screening of *RPGRIP1L*, a gene known to cause MKS and JBTS (Arts et al. 2007; Delous et al. 2007), for a cohort of patients with various ciliary disorder diagnoses (Khanna et al. 2009). Among the 10 novel nonsynonymous changes identified in *RPGRIP1L*, one allele (p.A229T) was enriched significantly in patients with ciliary disease coupled by retinal degeneration (Khanna et al. 2009; Table 1). The effect of the modifier allele was established in a zebrafish model in which it scored as pathogenic, and in a yeast two-hybrid screen in which the mutant *RPGRIP1L* was exerting a significantly lower affinity to form complexes with the retinitis pigmentosa GTPase regulator protein (RPGR), with which it inter-

acts (Khanna et al. 2009). It is thought that the observed photoreceptor degeneration in patients with the modifying *RPGRIP1L* p.A229T allele are because of the attenuation of the *RPGRIP1L*–*RPGR* interaction (Khanna et al. 2009). The observation that *RPGRIP1L* contributes modifying alleles was shown further in X-linked RP caused by mutations in *RPGR* (Fahim et al. 2011). Affected males from 56 families with *RPGR* mutations were genotyped for common alleles in each of *RPGRIP1*, *RPGRIP1L*, *CEP290*, and *IQCB1* based on the fact that they all interact with *RPGR* as determined by coimmunoprecipitation experiments (Boylan and Wright 2000; Otto et al. 2005; Chang et al. 2006; Khanna et al. 2009). Two alleles, the *IQCB1* p.I393N and the common *RPGRIP1L* p.R744Q, showed significant association with disease severity, with the minor allele in *IQCB1* and the common allele in *RPGRIP1L* being associated with more severe disease (Fahim et al. 2011).

In Usher syndrome, a genetically heterogeneous recessive disease characterized by hearing loss and RP, a genetic modifier of the retinal phenotype was identified by blasting for homologous proteins to harmonin causing Usher syndrome subtype 1C (*USH1C*) and whirlin underlying *USH2D* that cross-link other Usher proteins to form a multimolecular complex in the photoreceptors and hearing cells (Kremer et al. 2006; Ebermann et al. 2007). *PDZD7* was identified and screened for mutations in patients with an Usher syndrome diagnosis (Ebermann et al. 2010; Table 1). Although no changes in *PDZD7* were identified in Usher patients with any molecular diagnosis, in familial cases with mutations in known Usher genes, *PDZD7* seemed to be contributing to a digenic mode of inheritance and to also be contributing modifying alleles (Ebermann et al. 2010). For example, in a family with two *USH2A* (p.C1447QfsX29) affected sisters, the one that also carried a heterozygous frameshift mutation in *PDZD7* (p.R56PfsX24) displayed an earlier age of onset and more severe progression of RP, whereas in a distinct case of a family with two affected offspring, only the individual with a heterozygous *USH2C* (*GPR98* p.A5713LfsX3)

mutation and a second heterozygous hit in *PDZD7* is affected, suggesting that *GPR98* and *PDZD7* seem to be participating in a digenic mode of inheritance (Ebermann et al. 2010). Similar to the study identifying *RPGRIP1L* as a genetic modifier, the direction of effect of the *PDZD7* alleles as pathogenic and the digenic inheritance of *GPR98* and *PDZD7* were confirmed in a zebrafish in vivo model for RP (Ebermann et al. 2010).

BBS has contributed substantially to understanding the contribution of genetic modifiers to disease (Katsanis et al. 2001; Badano et al. 2006; Table 1). The disorder is genetically and clinically heterogeneous, with well-documented examples of inter- and intrafamilial phenotypic variability (Carmi et al. 1995; Riise et al. 1997). Although initially reported to follow an autosomal recessive mode of inheritance, BBS was the first disorder to follow a “triallelic” model of disease transmission with three alleles at two independent loci being required for disease manifestation (Katsanis et al. 2001). More specifically, in a nuclear family with one affected and two unaffected siblings, compound heterozygosity in *BBS2* for the nonsense alleles p.Y24X and p.Q59X was not sufficient to cause the phenotype, but required the presence of a third allele at a second BBS locus, *BBS6* p.Q147X, which acts essentially as a modifier of penetrance (Katsanis et al. 2001). A second example of genetic modification coming from the study of BBS samples is the identification of *CCDC28B* p.C430T as a modifier affecting RP; the patients that carried p.C430T displayed an earlier onset of RP and accelerated disease progression (Badano et al. 2006). In addition to contributing modifying alleles, *CCDC28B* has also been postulated to represent an example of complex inheritance because it seems to be required for disease manifestation in a family with *BBS1* p.M390R homozygous siblings and also asymptomatic father. It is therefore hypothesized that the third allele (p.C430T) located in *CCDC28B* might be required for disease manifestation or be acting as a modifier of penetrance similar to the *BBS6* and *BBS2* epistatic interaction (Beales et al. 2003; Badano et al. 2006).

M. Kousi and N. Katsanis

GENETIC MODIFIERS OF RETINAL DEGENERATION IN MICE

The cloning of modifiers in human genetic disorders is confounded by genetic and allelic heterogeneity. Some of these challenges can be overcome in model organisms. Laboratory mice in particular, have been successfully used to map modifier genes and alleles in a wide range of genetic disorders (Table 2). Although in most successful studies the modification of the primary phenotype is because of the effects of a single locus, independent from the primary locus (Danciger et al. 2000; Ikeda et al. 2002a), mapping of modifiers can be complicated when the modification results from the combined effects of several genes at discrete loci (Table 2) (Ikeda et al. 2002a).

The first report of a genetic modifier of retinal degeneration in mice was the identification of protective alleles in the *rd5* or tubby mouse for both the hearing and retinal degeneration phenotypes (Danciger et al. 2000; Ikeda et al. 2002a,b). The tubby mouse has been proposed as animal model for Usher syndrome 1, BBS and Alström syndrome because of the phenotypic convergence of the clinical phenotypes of retinal and cochlear degeneration, and maturity onset insulin-resistant obesity (Coleman and Eicher 1990; Heckenlively et al. 1995). Originally, the profound hearing loss in B6-*tub/tub* mice was fully rescued in F2 *tub/tub* homozygotes crossed with AKR/J, 129P2/OlaHsd and CAST/Ei mice, suggesting the presence of a protective allele (Ikeda et al. 2002a). Linkage analysis and subsequent sequencing identified 10 amino acid substitutions and an Ala-Pro repeat length difference in the microtubule-associated protein 1A (*Mtap1a*) residing within the modifier of *tubby* hearing 1 (*moth1*) locus on chromosome 2, between the B6-*tub/tub* and the *tub/tub* homozygotes in protective strains (Ikeda et al. 1999, 2002a). *Mtap1a* was suggested to play a role in vesicular trafficking of proteins to the neuronal synaptic junctions and further work demonstrating differential binding affinities of *Mtap1a* with the postsynaptic marker PSD95 support a role of the *Mtap1a* modifier gene in synaptic maintenance and architecture

(Brenman et al. 1998; Halpain and Dehmelt 2006). The second modifier hunt in the tubby strain consisted in the identification of the protective allele for the retinal degeneration phenotype of this model (Ikeda et al. 2002a). The degree of retinal degeneration was quantitatively assessed by measuring the thickness of the ONL and the number of photoreceptors in a defined area of the ONL between C57BL/6J-*tub/tub* mice and *tub/tub* homozygotes in the protective AKR/J strain (Ikeda et al. 2002a). Linkage analysis comparing the two strains identified a significant signal on chromosome 11, a locus termed modifier of *tubby* retinal degeneration 1 (*motr1*) whereby a recessive mode of inheritance was assumed for the mapping of the protective allele and two suggestive signals on chromosomes 2 and 8, where dominant protective alleles were likely to segregate (Ikeda et al. 2002a). Interestingly, the locus on chromosome 2 identified in the study for the retinal degeneration modifier, maps to the same locus as *moth1* harboring the *Mtap1a* hearing modifier (Ikeda et al. 2002a,b). Subsequent screening of *Mtap1a* revealed nonsynonymous sequence alterations between the C57BL/6J-*tub/tub* and AKR/J-*tub/tub* mice, suggesting that the same gene contributes protective alleles that account for the amelioration of both the hearing and retinal degeneration phenotypes of the *tubby* mouse (Maddox et al. 2012).

The use of ONL thickness as a quantitative trait that reflects retinal damage to perform linkage analysis led to the successful identification of a protective modifier in the *Rpe65* mouse model for light-induced photoreceptor damage, corresponding to human LCA (Akmedov et al. 2000). The two strains compared were C57BL/6J-c(2J) (c2J) albino mice that showed less damage to their photoreceptors after exposure to prolonged light than BALB/c mice and other albino strains, suggesting that the c2J strain was contributing protective allele(s) (Danciger et al. 2000). The strongest linkage signal was on chromosome 3; subsequent analyses led to the mapping of *Rpe65*, in which p.Leu450 was present on the BALB/c strain and was associated with light-induced photoreceptor damage, although the c2J strain carried the

Genetic Modifiers and Oligogenic Inheritance

Table 1. Genetic modifiers in retinal degeneration from studies in humans

Disorder	Primary disease driver	Second-site modifier	Clinical aspect affected by modifier	Reference(s)
BBS	<i>BBS2</i> (p.Y24X, p.Q59X)	<i>BBS6</i> (p.Q147X)	Disease penetrance; digenic inheritance	Katsanis et al. 2001
BBS		<i>MGC1203</i> (p.C430T)	Earlier onset of RP; accelerated disease progression	Badano et al. 2006
BBS	<i>BBS1</i> (p.M390R)	<i>MGC1203</i> (p.C430T)	Disease penetrance; digenic inheritance	Badano et al. 2006
Ciliopathies		<i>RPGRIP1L</i> (p.A229T)	Retinal degeneration	Khanna et al. 2009
Dominant cone or cone-rod dystrophy (COD3)	<i>GUCA1A</i> (p.P50 L)	Unknown	Disease severity	Downes et al. 2001
LCA	<i>CEP290</i>	<i>AHI1</i> (p.N811K and p.H758P)	Neurological phenotype; disease severity	Coppieters et al. 2010
LCA	<i>AIPL1</i> (p.Q163X)	<i>CRX</i> (p.T273L)	Earlier disease onset; disease severity	Zernant et al. 2005
LCA	<i>AIPL1</i> (p.R302 L)	<i>CRB1</i> (p.R1331H)	Accelerated disease progression	Zernant et al. 2005
LCA	<i>RPE65</i> (p.E102X)	<i>GUCY2D</i> (p.I573V)	Disease severity	Zernant et al. 2005
LCA	<i>GUCY2D</i> (p.S448X)	<i>CRX</i> (p.A158T)	Development of macular coloboma in both eyes	Zernant et al. 2005
Macular dystrophy	<i>PRPH2</i>	<i>ROM1</i> (p.R172 W or p.R229H)	Disease severity; loss of rod function	Poloschek et al. 2010
Macular dystrophy	<i>PRPH2</i>	<i>ABCA4</i> (p.R172 W, p.R229H or p.V2050L)	Aggravated disease course; loss of cone and rod function	Poloschek et al. 2010
Nephronophthisis Oguchi's disease/ autosomal recessive RP	<i>NPHP1</i> <i>SAG</i> (p.383fsX)	<i>AHI1</i> (p.R830 W) Unknown	Retinal degeneration Development of macular degeneration and golden-yellow fundus reflex	Louie et al. 2010 Nakazawa et al. 1998
Retinoschisis (X-linked)	<i>XLRS1</i> (p.125fsX)	Unknown	Disease severity and progression	Tantri et al. 2003
RP, pattern macular dystrophy, fundus flavimaculatus	<i>RDS</i> (p.L185P)	<i>ROM1</i> (p.114fsx)	Development of RP	Kajiwara et al. 1993; Weleber et al. 1993
RP (X-linked)	<i>RPGR</i>	<i>RPGRIP1L</i> (p.R744Q)	Disease severity	Fahim et al. 2011
RP (X-linked)	<i>RPGR</i>	<i>IQCB1</i> (p.I393N)	Disease severity	Fahim et al. 2011
RP (autosomal dominant)	<i>PRPF31</i>	<i>CNOT3</i>	Disease penetrance through transcriptional repression	Venturini et al. 2012

Continued

M. Kousi and N. Katsanis

Table 1. *Continued*

Disorder	Primary disease driver	Second-site modifier	Clinical aspect affected by modifier	Reference(s)
RP (autosomal dominant)	<i>PRPF31</i>	Unknown (linkage on 14q21-23)	Disease penetrance	Frio et al. 2008
RP1	<i>RPI</i> (p.R677X)	Unknown	Disease severity	Jacobson et al. 2000
RP9	<i>PAP-1</i> (p.H137 L)	Unknown	Disease severity	Keen et al. 2002; Kim et al. 1995
RP48	<i>GUCA1B</i> (p.G157R)	Unknown	Disease severity	Sato et al. 2005
Stargardt type 3	<i>ELOVL4</i> (5 bp deletion)	<i>ABCA4</i>	Disease severity ranging from Stargardt-like macular dystrophy to pattern dystrophy	Zhang et al. 1999; Bernstein et al. 2001
Sorby fundus dystrophy (SFD)	<i>TIMP3</i> (S181C)	Unknown	Pathological findings ranging from absence of fundus spots to yellow deposits associated with macular degeneration	Hamilton et al. 1989; Weber et al. 1994; Wijesuriya et al. 1996; Felbor et al. 1997
Usher syndrome	<i>USH2A</i> (p.C1447QfsX29)	<i>PDZD7</i> (p.R56PfsX24)	Earlier disease onset; aggravation of RP severity	Ebermann et al. 2010
Usher syndrome	<i>USH2C</i> (<i>GPR98</i> p.A5713LfsX3)	<i>PDZD7</i>	Disease penetrance; digenic inheritance	Ebermann et al. 2010
Usher syndrome	<i>USH1D</i> (p.R1746Q)	Unknown	Severity and progression of RP	Bolz et al. 2001; Astuto et al. 2002
Usher syndrome	<i>USH3A</i> (p.N48 K)	Unknown	Progression of RP	Ness et al. 2003
Vitelliform macular dystrophy type 2	<i>VMD2</i>	Unknown	Disease severity and penetrance; development of macular degeneration	Nordström and Thorburn 1980

p.Met450 that appeared to be driving the protection against light-induced damage (Danciger et al. 2000). The protective effect of *Rpe65* p.Met450 was also confirmed in other forms of retinal degeneration (Samardzija et al. 2006) and was supported further by introducing the allele in a *c-Fos*^{-/-} mouse (Wenzel et al. 2003). *C-Fos* is essential for light-induced photoreceptor apoptosis because of a sustained increase in the DNA-binding activity of AP-1 (Hafezi et al. 1997; Wenzel et al. 2000) and as a result *c-Fos*^{-/-} mice appear resistant to light-induced damage (Wenzel et al. 2000). When the endogenous *Rpe65* gene (carrying p.Met450) in *c-Fos*^{-/-} mice is substituted by *Rpe65* p.Leu450, *Rpe65* p.Leu450 resulted in an in-

crease in the levels of rhodopsin and therefore led to light-induced photoreceptor loss despite the protective role of *c-Fos* deficiency (Wenzel et al. 2003).

A third successful application of linkage analysis for the mapping of a quantitative trait locus (QTL) was performed in *Rs1* mouse model for X-linked retinoschisis (XLRS) (George et al. 1995; Johnson et al. 2010). XLRS is a form of juvenile-onset macular degeneration, whereby there is splitting of the retina (schisis) and loss of synaptic transmission (George et al. 1995; Johnson et al. 2010). When C57BL/6J *Rs1*^{tmgc1} mice were backcrossed into the AKR/J background, a recessive modifier seemed to be protecting *Rs1*^{tmgc1} mice from retinoschisis

Genetic Modifiers and Oligogenic Inheritance

Table 2. Genetic modifiers in retinal degeneration from studies in mice

Disorder	Primary disease driver/ mouse model	Second-site modifier	Phenotypic aspect affected by modifier	Strains involved	Reference(s)
Fibrous retrolental tissue	<i>p53</i>	Not identified	Disease penetrance	C57BL/6J, 129/SvJ	Ikeda et al. 1999
Glaucoma	<i>BMP4</i>	Not identified	Disease severity	C57BL/6J, BliA, CAST/Ei, C3H, AKR/J, BALB/C, 129/SvEvTac	Hong et al. 1999
Iris atrophy/ Glaucoma	<i>Ipd</i>	<i>Isa</i> (<i>Tyrrp1</i>)	Disease manifestation	C57BL/6J, DBA/2J	Chang et al. 1999
Iris pigment dispersion	<i>Ipd</i>	Not identified	Disease penetrance	AKXD-28/Ty	Anderson et al. 2001
Iris stromal atrophy	<i>Isa</i>	Not identified	Disease severity; increased cell death	AKXD-28/Ty	Anderson et al. 2001
LCA	<i>Rd16</i>	<i>Bbs6</i>	Variability in photoreceptor degeneration	C57BL/6J, 129/Sv, C57BL/6	Rachel et al. 2012
Light-induced retinal degeneration	<i>Rpe65</i>	<i>Rpe65</i> p.Leu450, <i>Rpe65</i> p.Met450	Disease penetrance	BALB/c2J	Danciger et al. 2000; Wenzel et al. 2003
Ocular retardation	<i>Chx10</i>	Not identified	Disease penetrance	CASA/Rk	Bone-Larson et al. 2000
Oguchi disease (stationary night blindness)	<i>Arrestin</i> ^{-/-}	<i>Arrestin</i> ^{P365/P365}	Light-damage susceptibility	C57BL/6, 129/SvJ	Chen et al. 1999
Light-induced RP	<i>Rho</i> ^{-/-}	<i>Rho</i> p.V20G, <i>Rho</i> p.P23H, <i>Rho</i> p.P27L	Disease penetrance	C57BL/6, FVB	Naash et al. 1996; Wang et al. 1997
Retinoschisis	<i>Rs1</i>	<i>Tyr</i> (<i>Mor1</i>)	Disease penetrance	C57BL/6J, AKR/J	Johnson et al. 2010
RP (recessive)	<i>Pde6a</i>	Not identified	Disease severity; photoreceptor loss rate	G3 A.B6- <i>Tyr</i> ⁺ /J	Sakamoto et al. 2009
RP1	<i>Rp1h</i>	Not identified	Disease severity	(N6) B6.129S, DBA.129S(B6), A.129S(B6)	Liu et al. 2009
RP	<i>Tub</i> or <i>Rd5</i>	<i>Mtap1a</i> (<i>motr1</i>)	RP penetrance; disease progression	B6.Cg- <i>rd5/rd5</i> , AKR/J	Ikeda et al. 2002b; Maddox et al. 2012
Retinal degeneration	<i>Rd3</i>	Not identified	Onset and progression of photoreceptor degeneration	RBF/Dn, Meta-In(1)Rk, Rb(11.13)4Bnr, In-30	Heckenlively et al. 1993

Continued

M. Kousi and N. Katsanis

Table 2. *Continued*

Disorder	Primary disease driver/ mouse model	Second-site modifier	Phenotypic aspect affected by modifier	Strains involved	Reference(s)
Retinal degeneration	<i>Rd7</i>	Chr 8 and 19 (CAST/EiJ), Chr 7 and 11 (AKR/J)	Suppression of retinal spotting	B6.Cg- <i>rd7/rd7</i> , CAST/EiJ, AKR/J, NOD.NON- <i>H2^{nb1}</i>	Akhmedov et al. 2000; Haider et al. 2008
Retinal degeneration	<i>Rho</i> ^{-/-}	Not identified	Variability in photoreceptor degeneration	129/SV, C57BL/6	Humphries et al. 2001
Retinal degeneration	<i>Rd16</i>	<i>Bbs4</i>	Variability in photoreceptor degeneration	129/SV, BXD24	Zhang et al. 2014

(George et al. 1995; Johnson et al. 2010). Linkage analysis identified the modifier for *Rs1* (*Mor1*) locus on chromosome 7 (Johnson et al. 2010). Within the critical interval mapped in AKR/J *Rs1^{tmgl}* mice, a recessive mutation in tyrosinase (*Tyr^{c-2J}*) was identified as the *Mor1* gene responsible for protection from the development of the schisis phenotype (George et al. 1995; Johnson et al. 2010).

CONCLUSIONS AND FUTURE PERSPECTIVES

Knowledge of the primary disease-causing mutation is rarely coupled by accurate prognosis. In many instances, the clinical phenotype of a patient with an identified driver mutation can either be ameliorated on the presence of protective alleles or exacerbated when disease-promoting alleles are present in the genome. Despite the numerous reports supporting the presence and importance of genetic modifiers, this field has not progressed as rapidly compared with the identification of primary disease drivers. One of the reasons for this difference, is our inability to recognize interactions among alleles and variants (Eichler et al. 2010). This is true not only for disorders considered to be monogenic but also for complex traits, in which “missing heritability,” the fraction of the genetic contribution not explained/explainable by single-locus analysis for rare or common alleles,

has been attributed, in part, to the presence of locus interactions and modifiers (Marchini et al. 2005; Zuk et al. 2012). It is possible to consider epistasis and genetic modification to uncover additional genetic contributions; in a study of ankylosing spondylitis, a common form of inflammatory arthritis, nonancestral *ERAP1* alleles have been shown to interact with disease predisposition alleles in *HLA-B27* to confer protection from disease manifestation (Evans et al. 2011). The protective role of *ERAP1* was validated further in a second multifactorial disorder, psoriasis, uncovering the interaction of this gene with *HLA-Cw6*, one of the major psoriasis susceptibility genes (Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, 2010). Despite the advances in the sequencing technologies, the number of successful genetic modifier identification studies remains small to date owing to many reasons such as the limited disease population sizes, genetic heterogeneity, the low frequency at which any particular combination of alleles is present in the population, and incomplete clinical descriptions (Flint and Mackay 2009). Animal models have provided a powerful tool for the identification of genetic modifiers. Congenic mouse strains have facilitated the mapping of protective and disease-aggravating alleles in a number of cases, some of which have been illustrated here. Zebrafish *in vivo* assays have aided in the functional annotation and

direction of effect of candidate alleles arising by such screens.

The most efficient method to unravel phenomena of genetic modification and oligogenic or complex inheritance, is to interrogate the identified candidate alleles starting from a discrete number of likely interacting loci. Higher throughput technologies provide a unique opportunity toward this goal; a complete genetic profile of cohorts or even specific cell types such as photoreceptors in retinal disorders can be generated through whole-exome or whole-genome sequencing providing the opportunity to mine the same data set multiple times to dissect specific and discrete endophenotypes associated with a genetic condition and its progression, and the development of induced pluripotent stem (iPS) cell technology offers the promise to provide differentiated products from individual human subjects. Although each of these methodologies appear promising, the majority of successful genetic modifier identification reports have relied on the combinatorial use of such tools. Shedding light into the field of genetic modifiers will lead to a more insightful comprehension of the affected pathways and cellular processes. Understanding the basis of disease is the only way toward designing new and more efficient therapeutic paradigms, improve prognosis and even prevent disease manifestation by attempting to mimic the effect of modifiers that affect disease penetrance.

REFERENCES

- Ackermann B, Kröber S, Torres-Benito L, Borgmann A, Peters M, Hosseini Barkooie SM, Tejero R, Jakubik M, Schreml J, Milbradt J, et al. 2013. Platin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. *Hum Mol Genet* **22**: 1328–1347.
- Akhmedov NB, Piriev NI, Chang B, Rapoport AL, Hawes NL, Nishina PM, Nusinowitz S, Heckenlively JR, Roderick TH, Kozak CA, et al. 2000. A deletion in a photoreceptor-specific nuclear receptor mRNA causes retinal degeneration in the *rd7* mouse. *Proc Natl Acad Sci* **97**: 5551–5556.
- Anderson M, Smith R, Savinova O, Hawes N, Chang B, Zabaleta A, Wilpan R, Heckenlively J, Davisson M, John S. 2001. Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice. *BMC Genet* **2**: 1.
- Apfelstedt-Sylla E, Theischen M, Rütger K, Wedemann H, Gal A, Zrenner E. 1995. Extensive intrafamilial and interfamilial phenotypic variation among patients with autosomal dominant retinal dystrophy and mutations in the human RDS/peripherin gene. *Br J Ophthalmol* **79**: 28–34.
- Arts HH, Doherty D, van Beersum SEC, Parisi MA, Lettboer SJE, Gordon NT, Peters TA, Marker T, Voesenek K, Kartono A, et al. 2007. Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. *Nat Genet* **39**: 882–888.
- Astuto LM, Bork JM, Weston MD, Askew JW, Fields RR, Orten DJ, Ohliger SJ, Riazuddin S, Morell RJ, Khan S, et al. 2002. *CDH23* mutation and phenotype heterogeneity: A profile of 107 diverse families with Usher Syndrome and nonsyndromic deafness. *Am J Hum Genet* **71**: 262–275.
- Baala L, Audollent S, Martinovic J, Ozilou C, Babron M-C, Sivanandamoorthy S, Saunier S, Salomon R, Gonzales M, Rattenberry E, et al. 2007. Pleiotropic effects of *CEP290* (*NPHP6*) mutations extend to Meckel syndrome. *Am J Hum Genet* **81**: 170–179.
- Badano JL, Katsanis N. 2002. Beyond Mendel: An evolving view of human genetic disease transmission. *Nat Rev Genet* **3**: 779–789.
- Badano JL, Kim JC, Hoskins BE, Lewis RA, Ansley SJ, Cutler DJ, Castellani C, Beales PL, Leroux MR, Katsanis N. 2003. Heterozygous mutations in *BBS1*, *BBS2* and *BBS6* have a potential epistatic effect on Bardet–Biedl patients with two mutations at a second BBS locus. *Hum Mol Genet* **12**: 1651–1659.
- Badano JL, Mitsuma N, Beales PL, Katsanis N. 2006. The ciliopathies: An emerging class of human genetic disorders. *Annu Rev Genomics Hum Genet* **7**: 125–148.
- Beales PL, Elcioglu N, Woolf AS, Parker D, Flintner FA. 1999. New criteria for improved diagnosis of Bardet–Biedl syndrome: Results of a population survey. *J Med Genet* **36**: 437–446.
- Beales PL, Badano JL, Ross AJ, Ansley SJ, Hoskins BE, Kirsten B, Mein CA, Froguel P, Scambler PJ, Lewis RA, et al. 2003. Genetic interaction of *BBS1* mutations with alleles at other *BBS* loci can result in non-Mendelian Bardet–Biedl syndrome. *Am J Hum Genet* **72**: 1187–1199.
- Bernstein PS, Tammur J, Singh N, Hutchinson A, Dixon M, Pappas CM, Zabriskie NA, Zhang K, Petrukhin K, Lepert M, et al. 2001. Diverse macular dystrophy phenotype caused by a novel complex mutation in the *ELOVL4* gene. *Invest Ophthalmol Vis Sci* **42**: 3331–3336.
- Bolk S, Pelet A, Hofstra RMW, Angrist M, Salomon R, Croaker D, Buys CHCM, Lyonnet S, Chakravarti A. 2000. A human model for multigenic inheritance: Phenotypic expression in Hirschsprung disease requires both the *RET* gene and a new 9q31 locus. *Proc Natl Acad Sci* **97**: 268–273.
- Bolz H, von Brederlow B, Ramirez A, Bryda EC, Kutsche K, Nothwang HG, Seeliger M, Cabrera MdCS, Vila MC, Molina OB, et al. 2001. Mutation of *CDH23*, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. *Nat Genet* **27**: 108–112.
- Bone-Larson C, Basu S, Radel JD, Liang M, Perozek T, Kapousta-Bruneau N, Green DG, Burmeister M, Hankin

M. Kousi and N. Katsanis

- MH. 2000. Partial rescue of the ocular retardation phenotype by genetic modifiers. *J Neurobiol* **42**: 232–247.
- Borrego S, Ruiz A, Saez ME, Gimm O, Gao X, López-Alonso M, Hernández A, Wright FA, Antiñolo G, Eng C. 2000. *RET* genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. *J Med Genet* **37**: 572–578.
- Boylan JP, Wright AF. 2000. Identification of a novel protein interacting with RPGR. *Hum Mol Genet* **9**: 2085–2093.
- Brattgard S. 1949. The pathology of the Laurence-Moon-Biedl syndrome. *Acta Path Microbiol Scand* **26**: 525–537.
- Brennan JE, Topinka JR, Cooper EC, McGee AW, Rosen J, Milroy T, Ralston HJ, Bredt DS. 1998. Localization of postsynaptic density-93 to dendritic microtubules and interaction with microtubule-associated protein 1A. *J Neurosci* **18**: 8805–8813.
- Carmi R, Elbedour K, Stone EM, Sheffield VC. 1995. Phenotypic differences among patients with Bardet-Biedl syndrome linked to three different chromosome loci. *Am J Med Genet* **59**: 199–203.
- Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A. 2002. Genome-wide association study and mouse model identify interaction between *RET* and *EDNRB* pathways in Hirschsprung disease. *Nat Genet* **32**: 237–244.
- Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, Savinova O, Roderick TH, Heckenlively JR, Davisson MT, John SWM. 1999. Interacting loci cause severe iris atrophy and glaucoma in *DBA/2J* mice. *Nat Genet* **21**: 405–409.
- Chang B, Khanna H, Hawes N, Jimeno D, He S, Lillo C, Parapuram SK, Cheng H, Scott A, Hurd RE, et al. 2006. In-frame deletion in a novel centrosomal/ciliary protein *CEP290/NPHP6* perturbs its interaction with RPGR and results in early-onset retinal degeneration in the *rd16* mouse. *Hum Mol Genet* **15**: 1847–1857.
- Chen J, Simon MI, Matthes MT, Yasumura D, LaVail MM. 1999. Increased susceptibility to light damage in an arrestin knockout mouse model of Oguchi disease (stationary night blindness). *Invest Ophthalmol Vis Sci* **40**: 2978–2982.
- Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, Wells S, Bruning JC, Nolan PM, Ashcroft FM, et al. 2010. Overexpression of *Fto* leads to increased food intake and results in obesity. *Nat Genet* **42**: 1086–1092.
- Coleman DL, Eicher EM. 1990. Fat (*fat*) and tubby (*tubby*): Two autosomal recessive mutations causing obesity syndromes in the mouse. *J Hered* **81**: 424–427.
- Coppieters F, Casteels I, Meire F, De Jaegere S, Hooghe S, van Regemorter N, Van Esch H, Matulevičienė A, Nunes L, Meersschaet V, et al. 2010. Genetic screening of LCA in Belgium: Predominance of *CEP290* and identification of potential modifier alleles in *AHI1* of *CEP290*-related phenotypes. *Hum Mutat* **31**: E1709–E1766.
- Cutting GR. 2010. Modifier genes in Mendelian disorders: The example of cystic fibrosis. *Ann NY Acad Sci* **1214**: 57–69.
- Czeizel AE, Dudás I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* **327**: 1832–1835.
- Danciger M, Matthes MT, Yasumura D, Akhmedov NB, Rickabaugh T, Gentleman S, Redmond TM, La Vail MM, Farber DB. 2000. A QTL on distal Chromosome 3 that influences the severity of light-induced damage to mouse photoreceptors. *Mamm Genome* **11**: 422–427.
- Danciger M, Ogando D, Yang H, Matthes MT, Yu N, Ahern K, Yasumura D, Williams RW, LaVail MM. 2008. Genetic modifiers of retinal degeneration in the *rd3* mouse. *Invest Ophthalmol Vis Sci* **49**: 2863–2869.
- Darrah R, McKone E, O'Connor C, Rodgers C, Genatossio A, McNamara S, Gibson R, Stuart Elborn J, Ennis M, et al. 2010. *EDNRA* variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. *Physiol Genomics* **41**: 71–77.
- Davis EE, Katsanis N. 2012. The ciliopathies: A transitional model into systems biology of human genetic disease. *Curr Opin Genet Dev* **22**: 290–303.
- Delous M, Baala L, Salomon R, Laclef C, Vierkotten J, Tory K, Golzio C, Lacoste T, Besse L, Ozilou C, et al. 2007. The ciliary gene *RPGRIP1L* is mutated in cerebello-ocular syndrome (Joubert syndrome type B) and Meckel syndrome. *Nat Genet* **39**: 875–881.
- den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KEJ, Zonneveld MN, Strom TM, Meitinger T, Brunner HG, et al. 2006. Mutations in the *CEP290* (*NPHP6*) gene are a frequent cause of Leber congenital amaurosis. *Am J Hum Genet* **79**: 556–561.
- den Hollander AI, Roepman R, Koenekoop RK, Cremers FPM. 2008. Leber congenital amaurosis: Genes, proteins and disease mechanisms. *Prog Retin Eye Res* **27**: 391–419.
- Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, Carlsson LMS, Kiess W, Vatin V, Lecoer C, et al. 2007. Variation in *FTO* contributes to childhood obesity and severe adult obesity. *Nat Genet* **39**: 724–726.
- Dipple KM, McCabe ERB. 2000. Phenotypes of patients with “simple” Mendelian disorders are complex traits: Thresholds, modifiers, and systems dynamics. *Am J Hum Genet* **66**: 1729–1735.
- Downes SM, Holder GE, Fitzke FW, et al. 2001. Autosomal dominant cone and cone-rod dystrophy with mutations in the guanylate cyclase activator 1a gene-encoding guanylate cyclase activating protein-1. *Arch Ophthalmol* **119**: 96–105.
- Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al. 2005. Genetic modifiers of lung disease in cystic fibrosis. *N Engl J Med* **353**: 1443–1453.
- Dryja TP, McGee TL, Hahn LB, Cowley GS, Olsson JE, Reichel E, Sandberg MA, Berson EL. 1990. Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. *N Engl J Med* **323**: 1302–1307.
- Ebermann I, Scholl HN, Charbel Issa P, Becirovic E, Lamprecht J, Jurkles B, Millán J, Aller E, Mitter D, Bolz H. 2007. A novel gene for Usher syndrome type 2: Mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss. *Hum Genet* **121**: 203–211.
- Ebermann I, Phillips JB, Liebau MC, Koenekoop RK, Schermer B, Lopez I, Schaefer E, Roux A-F, et al. 2010. *PDZD7* is a modifier of retinal disease and a contributor to digenic Usher syndrome. *J Clin Invest* **120**: 1812–1823.

- Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, Nadeau JH. 2010. Missing heritability and strategies for finding the underlying causes of complex disease. *Nat Rev Genet* **11**: 446–450.
- Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, Lin S, Portnoy ME, Cutler DJ, Green ED, Chakravarti A. 2005. A common sex-dependent mutation in a *RET* enhancer underlies Hirschsprung disease risk. *Nature* **434**: 857–863.
- Evans DM, Spencer CCA, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Diltz A, Pirinen M, Stone MA, et al. 2011. Interaction between *ERAP1* and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet* **43**: 761–767.
- Fahim AT, Bowne SJ, Sullivan LS, Webb KD, Williams JT, Wheaton DK, Birch DG, Daiger SP. 2011. Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to *RPGR* mutations. *PLoS ONE* **6**: e23021.
- Felbor U, Benkowitz C, Klein ML, Greenberg J, Gregory CY, Weber BF. 1997. Sorsby fundus dystrophy: Reevaluation of variable expressivity in patients carrying a *TIMP3* founder mutation. *Arch Ophthalmol* **115**: 1569–1571.
- Flint J, Mackay TFC. 2009. Genetic architecture of quantitative traits in mice, flies, and humans. *Genome Res* **19**: 723–733.
- Frank V, Ortiz Brühl N, Mager S, Frints SGM, Bohring A, du Bois G, Debatin I, Seidel H, Senderek J, Besbas N, et al. 2007. Aberrant splicing is a common mutational mechanism in *MKSI*, a key player in Meckel-Gruber syndrome. *Hum Mutat* **28**: 638–639.
- Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JRB, Elliott KS, Lango H, Rayner NW, et al. 2007. A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**: 889–894.
- Frio TR, Civic N, Ransijn A, Beckmann JS, Rivolta C. 2008. Two trans-acting eQTLs modulate the penetrance of *PRPF31* mutations. *Hum Mol Genet* **17**: 3154–3165.
- Gabriel SB, Salomon R, Pelet A, Angrist M, Amiel J, Fornage M, Attie-Bitach T, Olson JM, Hofstra R, Buys C, et al. 2002. Segregation at three loci explains familial and population risk in Hirschsprung disease. *Nat Genet* **31**: 89–93.
- Garcia-Barceló M-M, Sham M-H, Lui VC-H, Chen BL-S, Song Y-Q, Lee W-S, Yung S-K, Romeo G, Tam PK-H. 2003. Chinese patients with sporadic Hirschsprung's disease are predominantly represented by a single *RET* haplotype. *J Med Genet* **40**: e122.
- Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Fiby N, Schwartz M, Koch C. 1999. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. *J Clin Invest* **104**: 431–437.
- Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C, et al. 2010. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between *HLA-C* and *ERAP1*. *Nat Genet* **42**: 985–990.
- Génin E, Feingold J, Clerget-Darpoux F. 2008. Identifying modifier genes of monogenic disease: Strategies and difficulties. *Hum Genet* **124**: 357–368.
- George ND, Yates JR, Moore AT. 1995. X linked retinoschisis. *Br J Ophthalmol* **79**: 697–702.
- Gershoni-Baruch R, Nachlieli T, Leibo R, Degani S, Weissman I. 1992. Cystic kidney dysplasia and polydactyly in 3 sibs with Bardet-Biedl syndrome. *Am J Med Genet* **44**: 269–273.
- Gherman A, Davis EE, Katsanis N. 2006. The ciliary proteome database: An integrated community resource for the genetic and functional dissection of cilia. *Nat Genet* **38**: 961–962.
- Gibson G. 2012. Rare and common variants: Twenty arguments. *Nat Rev Genet* **13**: 135–145.
- Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L. 2007. The human disease network. *Proc Natl Acad Sci* **104**: 8685–8690.
- Goldberg AFX, Molday RS. 1996. Defective subunit assembly underlies a digenic form of retinitis pigmentosa linked to mutations in peripherin/rds and rom-1. *Proc Natl Acad Sci* **93**: 13726–13730.
- Goss CH, Newsom SA, Schildcrout JS, Sheppard L, Kaufman JD. 2004. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. *Am J Respir Crit Care Med* **169**: 816–821.
- Gouya LDJ, Lamoril J, Da Silva V, Beaumont C, Grandchamp B, Nordmann Y. 1996. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. *Am J Hum Genet* **58**: 292–299.
- Gouya L, Puy H, Robreau A-M, Bourgeois M, Lamoril J, Da Silva V, Grandchamp B, Deybach J-C. 2002. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype *FECH*. *Nat Genet* **30**: 27–28.
- Gouya L, Martin-Schmitt C, Robreau A-M, Austerlitz F, Da Silva V, Brun P, Simonin S, Lyoumi S, Grandchamp B, Beaumont C, et al. 2006. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. *Am J Hum Genet* **78**: 2–14.
- Grunnet LG, Brøns C, Jacobsen S, Nilsson E, Astrup A, Hansen T, Pedersen O, Poulsen P, Quistorff B, Vaag A. 2009. Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of *FTO* rs9939609. *J Clin Endocrinol Metab* **94**: 596–602.
- Gusella J, MacDonald M. 2009. Huntington's disease: The case for genetic modifiers. *Genome Med* **1**: 80.
- Hafezi F, Steinbach JP, Marti A, Munz K, Wang ZQ, Wagner EF, Aguzzi A, Remé CE. 1997. The absence of *c-fos* prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. *Nat Med* **3**: 346–349.
- Haider N, Zhang W, Hurd R, Ikeda A, Nystuen A, Naggert J, Nishina P. 2008. Mapping of genetic modifiers of *Nr2e3^{rd7/rd7}* that suppress retinal degeneration and restore blue cone cells to normal quantity. *Mamm Genome* **19**: 145–154.

M. Kousi and N. Katsanis

- Haldane J. 1941. The relative importance of principal and modifying genes in determining some human diseases. *J Genet* **41**: 149–157.
- Halpain S, Dehmelt L. 2006. The MAP1 family of microtubule-associated proteins. *Genome Biol* **7**: 224.
- Hamilton WK, Ewing CC, Ives EJ, Carruthers JD. 1989. Sorsby's Fundus Dystrophy. *Ophthalmology* **96**: 1755–1762.
- Heckenlively JR, Chang B, Peng C, Hawes NL, Roderick TH. 1993. Variable expressivity of rd-3 retinal degeneration dependent on background strain. In *Retinal degeneration* (ed. Hollyfield JG, Anderson RE, LaVail MM), pp. 273–280. Plenum, New York.
- Heckenlively JR, Chang B, Erway LC, Peng C, Hawes NL, Hageman GS, Roderick TH. 1995. Mouse model for Usher syndrome: Linkage mapping suggests homology to Usher type I reported at human chromosome 11p15. *Proc Natl Acad Sci* **92**: 11100–11104.
- Hillman AD, Londono D, Dunn JM, Goddard KAB, Pace RG, Knowles MR, Drumm ML. 2008. Modulation of cystic fibrosis lung disease by variants in interleukin-8. *Genes Immun* **9**: 501–508.
- Hong H-K, Lass JH, Chakravarti A. 1999. Pleiotropic skeletal and ocular phenotypes of the mouse mutation congenital hydrocephalus (*ch/Mfl*) arise from a winged helix/forkhead transcription factor gene. *Hum Mol Genet* **8**: 625–637.
- Humphries MM, Kiang S, McNally N, Donovan MA, Sieving PA, Bush RA, Machida S, Cotter T, Hobson A, Farrar J, et al. 2001. Comparative structural and functional analysis of photoreceptor neurons of *Rho*^{-/-} mice reveal increased survival on C57BL/6J in comparison to 129Sv genetic background. *Vis Neurosci* **18**: 437–443.
- Ikeda A, Yin Zheng Q, Rosenstiel P, Maddatu T, Zuberi AR, Roopenian DC, North MA, Naggert JK, Johnson KR, Nishina PM. 1999. Genetic modification of hearing in tubby mice: Evidence for the existence of a major gene (*moth1*) which protects tubby mice from hearing loss. *Hum Mol Genet* **8**: 1761–1767.
- Ikeda A, Naggert JK, Nishina PM. 2002a. Genetic modification of retinal degeneration in tubby mice. *Exp Eye Res* **74**: 455–461.
- Ikeda A, Zheng QY, Zuberi AR, Johnson KR, Naggert JK, Nishina PM. 2002b. Microtubule-associated protein 1A is a modifier of tubby hearing (*moth1*). *Nat Genet* **30**: 401–405.
- Jacobson SG, Cideciyan AV, Iannaccone A, Weleber RG, Fishman GA, Maguire AM, Affatigato LM, Bennett J, Pierce EA, Danciger M, et al. 2000. Disease expression of RP1 mutations causing autosomal dominant retinitis pigmentosa. *Invest Ophthalmol Vis Sci* **41**: 1898–1908.
- Johnson BA, Cole BS, Geisert EE, Ikeda S, Ikeda A. 2010. Tyrosinase is the modifier of retinosis in mice. *Genetics* **186**: 1337–1344.
- Kajiwaru K, Sandberg MA, Berson EL, Dryja TP. 1993. A null mutation in the human peripherin/RDS gene in a family with autosomal dominant retinitis punctata albescens. *Nat Genet* **3**: 208–212.
- Kajiwaru K, Berson E, Dryja T. 1994. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. *Science* **264**: 1604–1608.
- Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, Scambler PJ, Davidson WS, Beales PL, Lupski JR. 2001. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. *Science* **293**: 2256–2259.
- Keen TJ, Himms MM, McKie AB, Moore AT, Doran RM, Mackey DA, Mansfield DC, Mueller RF, Bhattacharya SS, Bird AC, et al. 2002. Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa. *Eur J Hum Genet* **10**: 245–249.
- Kerem BS, Zielinski J, Markiewicz D, Bozon D, Gazit E, Yahav J, Kennedy D, Riordan JR, Collins FS, Rommens JM. 1990. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. *Proc Natl Acad Sci* **87**: 8447–8451.
- Khanna H, Davis EE, Murga-Zamalloa CA, Estrada-Cuzcano A, Lopez I, den Hollander AI, Zonneveld MN, Othman MI, Waseem N, Chakarova CF, et al. 2009. A common allele in *RPGRIPL* is a modifier of retinal degeneration in ciliopathies. *Nat Genet* **41**: 739–745.
- Kim RY, Fitzke FW, Moore AT, Jay M, Inglehearn C, Arden GB, Bhattacharya SS, Bird AC. 1995. Autosomal dominant retinitis pigmentosa mapping to chromosome 7p exhibits variable expression. *Br J Ophthalmol* **79**: 23–27.
- Klötting N, Schleinitz D, Ruschke K, Berndt J, Fasshauer M, Tönjes A, Schön MR, Kovacs P, Stumvoll M, Blüher M. 2008. Inverse relationship between obesity and *FTO* gene expression in visceral adipose tissue in humans. *Diabetologia* **51**: 641–647.
- Kremer H, van Wijk E, Märker T, Wolfrum U, Roepman R. 2006. Usher syndrome: Molecular links of pathogenesis, proteins and pathways. *Hum Mol Genet* **15**: R262–R270.
- Labrune M, Gaux JC, Brault B. 1974. The Laurence-Moon-Bardet-Biedl syndrome. Urographic signs. *Ann Radiol* **17**: 385–389.
- Landau J, Bromberg Y, Schorr J. 1949. Laurence-Moon-Biedl syndrome with multiple congenital malformations of the urinary tract. *Acta Med Orient* **8**: 205–210.
- Laurence KM, James N, Miller M, Campbell H. 1980. Increased risk of recurrence of pregnancies complicated by fetal neural tube defects in mothers receiving poor diets, and possible benefit of dietary counselling. *BMJ* **281**: 1592–1594.
- Leitch CC, Zaghoul NA, Davis EE, Stoetzel C, Diaz-Font A, Rix S, Alfadhel M, Lewis RA, Eyaid W, Banin E, et al. 2008. Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome. *Nat Genet* **40**: 443–448.
- Li JB, Gerdes JM, Haycraft CJ, Fan Y, Teslovich TM, May-Simera H, Li H, Blacque OE, Li L, Leitch CC, et al. 2004. Comparative genomics identifies a flagellar and basal body proteome that includes the *BBS5* human disease gene. *Cell* **117**: 541–552.
- Lim J, Hao T, Shaw C, Patel AJ, Szabó G, Rual J-F, Fisk CJ, Li N, Smolyar A, Hill DE, et al. 2006. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. *Cell* **125**: 801–814.
- Liu Q, Saveliev A, Pierce EA. 2009. The severity of retinal degeneration in *Rp1h* gene-targeted mice is dependent

- on genetic background. *Invest Ophthalmol Vis Sci* **50**: 1566–1574.
- Loewen CJR, Moritz OL, Molday RS. 2001. Molecular characterization of peripherin-2 and rom-1 mutants responsible for digenic retinitis pigmentosa. *J Biol Chem* **276**: 22388–22396.
- Louie CM, Caridi G, Lopes VS, Brancati F, Kispert A, Lancaster MA, Schlossman AM, Otto EA, Leitges M, Grone H-J, et al. 2010. *AH1* is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis. *Nat Genet* **42**: 175–180.
- Lyon AN, Pineda RH, Hao IT, Kudryashova E, Kudryashov DS, Beattie CE. 2014. Calcium binding is essential for plastin 3 function in Smn-deficient motoneurons. *Hum Mol Genet* **23**: 1990–2004.
- Maddox DM, Ikeda S, Ikeda A, Zhang W, Krebs MP, Nishina PM, Naggert JK. 2012. An allele of microtubule-associated protein 1A (*Mtap1a*) reduces photoreceptor degeneration in *Tulp1* and *Tub* mutant mice. *Invest Ophthalmol Vis Sci* **53**: 1663–1669.
- Magro F, Peres E. 1970. Nefropathia do síndrome do Laurence–Moon–Bardet–Biedl. *Revista Iberica de Endocrinologia* **17**: 243–253.
- Marchini J, Donnelly P, Cardon LR. 2005. Genome-wide strategies for detecting multiple loci that influence complex diseases. *Nat Genet* **37**: 413–417.
- Margolin DH, Kousi M, Chan Y-M, Lim ET, Schmahmann JD, Hadjivassiliou M, Hall JE, Adam I, Dwyer A, Plummer L, et al. 2013. Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. *N Engl J Med* **368**: 1992–2003.
- McWilliam P, Farrar GJ, Kenna P, Bradley DG, Humphries MM, Sharp EM, McConnell DJ, Lawler M, Sheils D, Ryan C, et al. 1989. Autosomal dominant retinitis pigmentosa (ADRP): Localization of an ADRP gene to the long arm of chromosome 3. *Genomics* **5**: 619–622.
- Naash ML, Peachey NS, Li ZY, Gryczan CC, Goto Y, Blanks J, Milam AH, Ripps H. 1996. Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. *Invest Ophthalmol Vis Sci* **37**: 775–782.
- Nakazawa M, Wada Y, Tamai M. 1998. Arrestin gene mutations in autosomal recessive retinitis pigmentosa. *Arch Ophthalmol* **116**: 498–501.
- Ness SL, Ben-Yosef T, Bar-Lev A, Madeo AC, Brewer CC, Avraham KB, Kornreich R, Desnick RJ, Willner JP, Friedman TB, et al. 2003. Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. *J Med Genet* **40**: 767–772.
- Nordström S, Thorburn W. 1980. Dominantly inherited macular degeneration (Best's disease) in a homozygous father with 11 children. *Clin Genet* **18**: 211–216.
- Ohlemiller KK, Hughes RM, Lett JM, Ogilvie JM, Speck JD, Wright JS, Faddis BT. 1997. Progression of cochlear and retinal degeneration in the *tubby* (*rd5*) mouse. *Audiol Neurotol* **2**: 175–185.
- Oprea GE, Kröber S, McWhorter ML, Rossoll W, Müller S, Krawczak M, Bassell GJ, Beattie CE, Wirth B. 2008. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. *Science* **320**: 524–527.
- Otto EA, Loeys B, Khanna H, Hellemans J, Sudbrak R, Fan S, Muerb U, O'Toole JF, Helou J, Attanasio M, et al. 2005. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. *Nat Genet* **37**: 282–288.
- Perrault I, Delphin N, Hanein S, Gerber S, Dufier J-L, Roche O, Defoort-Dhellemmes S, Dollfus H, Fazzi E, Munnich A, et al. 2007. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. *Hum Mutat* **28**: 416–416.
- Poloschek CM, Bach M, Lagrèze WA, Glaus E, Lemke JR, Berger W, Neidhardt J. 2010. *ABCA4* and *ROM1*: Implications for modification of the *PRPH2*-associated macular dystrophy phenotype. *Invest Ophthalmol Vis Sci* **51**: 4253–4265.
- Rachel RA, May-Simera HL, Veleri S, Gotoh N, Choi BY, Murga-Zamalloa C, McIntyre JC, Marek J, Lopez I, Hackett AN, et al. 2012. Combining *Cep290* and *Mkks* ciliopathy alleles in mice rescues sensory defects and restores ciliogenesis. *J Clin Invest* **122**: 1233–1245.
- Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S, Gowrisankar S, Vemuri S, Montgomery K, Yu Y, et al. 2011. A rare penetrant mutation in *CFH* confers high risk of age-related macular degeneration. *Nat Genet* **43**: 1232–1236.
- Riazuddin SA, Shahzadi A, Zeitz C, Ahmed ZM, Ayyagari R, Chavali VRM, Ponferrada VG, Audo I, Michiels C, Lancelot M-E, et al. 2010. A mutation in *SLC24A1* implicated in autosomal-recessive congenital stationary night blindness. *Am J Hum Genet* **87**: 523–531.
- Riise R, Andréasson S, Borgström MK, Wright AF, Tommerup N, Rosenberg T, Tornqvist K. 1997. Intrafamilial variation of the phenotype in Bardet–Biedl syndrome. *Br J Ophthalmol* **81**: 378–385.
- Rivolta C, Sharon D, DeAngelis MM, Dryja TP. 2002. Retinitis pigmentosa and allied diseases: Numerous diseases, genes, and inheritance patterns. *Hum Mol Genet* **11**: 1219–1227.
- Rubin BK. 1990. Exposure of children with cystic fibrosis to environmental tobacco smoke. *N Engl J Med* **323**: 782–788.
- Sakamoto K, McCluskey M, Wensel TG, Naggert JK, Nishina PM. 2009. New mouse models for recessive retinitis pigmentosa caused by mutations in the *Pde6a* gene. *Hum Mol Genet* **18**: 178–192.
- Samardzija M, Wenzel A, Naash M, Remé CE, Grimm C. 2006. *Rpe65* as a modifier gene for inherited retinal degeneration. *Eur J Neurosci* **23**: 1028–1034.
- Sancandi M, Griseri P, Pesce B, Patrone G, Puppo F, Lerone M, Martucciello G, Romeo G, Ravazzolo R, Devoto M, et al. 2003. Single nucleotide polymorphic alleles in the 5' region of the *RET* proto-oncogene define a risk haplotype in Hirschsprung's disease. *J Med Genet* **40**: 714–718.
- Sato M, Nakazawa M, Usui T, Tanimoto N, Abe H, Ohguro H. 2005. Mutations in the gene coding for guanylate cyclase-activating protein 2 (*GUCA1B* gene) in patients with autosomal dominant retinal dystrophies. *Graefes Arch Clin Exp Ophthalmol* **243**: 235–242.
- Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, et al. 2006. The centrosomal protein nephrocystin-6 is

M. Kousi and N. Katsanis

- mutated in Joubert syndrome and activates transcription factor ATF4. *Nat Genet* **38**: 674–681.
- Schäffer AA. 2013. Digenic inheritance in medical genetics. *J Med Genet* **50**: 641–652.
- Scuteri A, Sanna S, Chen W-M, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, Orrú M, Usala G, et al. 2007. Genome-wide association scan shows genetic variants in the *FTO* gene are associated with obesity-related traits. *PLoS Genet* **3**: e115.
- Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, Goldstein JL, Triebwasser M, Anderson HE, Zerbib J, et al. 2013. Rare variants in *CFI*, *C3* and *C9* are associated with high risk of advanced age-related macular degeneration. *Nat Genet* **45**: 1366–1370.
- Smemo S, Tena JJ, Kim K-H, Gamazon ER, Sakabe NJ, Gomez-Marín C, Aneas I, Credidio FL, Sobreira DR, Wasserman NE, et al. 2014. Obesity-associated variants within *FTO* form long-range functional connections with *IRX3*. *Nature* **507**: 371–375.
- Speilman RS, McGinnis RE, Ewens WJ. 1993. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet* **52**: 506–516.
- Stoetzel C, Laurier V, Davis EE, Muller J, Rix S, Badano JL, Leitch CC, Salem N, Chouery E, Corbani S, et al. 2006. *BBS10* encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus. *Nat Genet* **38**: 521–524.
- Stoetzel C, Muller J, Laurier V, Davis EE, Zaghoul NA, Vicaire S, Jacquelin C, Plewniak F, Leitch CC, Sarda P, et al. 2007. Identification of a novel BBS gene (*BBS12*) highlights the major role of a vertebrate-specific branch of chaperonin-related proteins in Bardet-Biedl syndrome. *Am J Hum Genet* **80**: 1–11.
- Tantri A, Vrabec TR, Cu-Unjieng A, Frost A, Annesley WH Jr, Donoso LA. 2003. X-linked retinoschisis: Report of a family with a rare deletion in the *xLRS1* gene. *Am J Ophthalmol* **136**: 547–549.
- Tolarova M. 1982. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. *Lancet* **320**: 217.
- Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami SR, Castori M, Lancaster MA, Boltshauser E, Boccone L, Al-Gazali L, et al. 2006. Mutations in *CEP290*, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat Genet* **38**: 623–625.
- Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, et al. 2007. Heritability of lung disease severity in cystic fibrosis. *Am J Respir Crit Care Med* **175**: 1036–1043.
- Venturini G, Rose AM, Shah AZ, Bhattacharya SS, Rivolta C. 2012. *CNOT3* is a modifier of *PRPF31* mutations in retinitis pigmentosa with incomplete penetrance. *PLoS Genet* **8**: e1003040.
- Wald NJ, Law MR, Morris JK, Wald DS. 2001. Quantifying the effect of folic acid. *Lancet* **358**: 2069–2073.
- Walia S, Fishman GA, Swaroop A, Branham KEH, Lindemena M, Othman M, Weleber RG. 2008. Discordant phenotypes in fraternal twins having an identical mutation in exon ORF15 of the *RPGR* gene. *Arch Ophthalmol* **126**: 379–384.
- Wang M, Lam TT, Tso MOM, Naash MI. 1997. Expression of a mutant opsin gene increases the susceptibility of the retina to light damage. *Vis Neurosci* **14**: 55–62.
- Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U. 1994. Mutations in the tissue inhibitor of metalloproteinases-3 (*TIMP3*) in patients with Sorsby's fundus dystrophy. *Nat Genet* **8**: 352–356.
- Weleber RG, Carr RE, Murphey WH, Sheffield VC, Stone EM. 1993. Phenotypic variation including retinitis pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of codon 153 or 154 of the peripherin/*RDS* gene. *Arch Ophthalmol* **111**: 1531–1542.
- Wenzel A, Grimm C, Marti A, Kueng-Hitz N, Hafezi F, Niemeyer G, Remé CE. 2000. *c-fos* controls the “private pathway” of light-induced apoptosis of retinal photoreceptors. *J Neurosci* **20**: 81–88.
- Wenzel A, Grimm C, Samardzija M, Remé CE. 2003. The genetic modifier *Rpe65^{Leu450}*: Effect on light damage susceptibility in *c-Fos*-deficient mice. *Invest Ophthalmol Vis Sci* **44**: 2798–2802.
- Wijesuriya SD, Evans K, Jay MR, Davison C, Weber BH, Bird AC, Bhattacharya SS, Gregory CY. 1996. Sorsby's fundus dystrophy in the British Isles: Demonstration of a striking founder effect by microsatellite-generated haplotypes. *Genome Res* **6**: 92–101.
- Zernant J, Külm M, Dharmaraj S, den Hollander AI, Perault I, Preising MN, Lorenz B, Kaplan J, Cremers FPM, Maumenee I, et al. 2005. Genotyping microarray (disease chip) for Leber congenital amaurosis: Detection of modifier alleles. *Invest Ophthalmol Vis Sci* **46**: 3052–3059.
- Zhang K, Kniazeva M, Hutchinson A, Han M, Dean M, Allikmets R. 1999. The *ABCR* gene in recessive and dominant Stargardt diseases: A genetic pathway in macular degeneration. *Genomics* **60**: 234–237.
- Zhang Y, Seo S, Bhattarai S, Bugge K, Searby CC, Zhang Q, Drack AV, Stone EM, Sheffield VC. 2014. BBS mutations modify phenotypic expression of *CEP290*-related ciliopathies. *Hum Mol Genet* **23**: 40–51.
- Zuk O, Hechter E, Sunyaev SR, Lander ES. 2012. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proc Natl Acad Sci* **109**: 1193–1198.

Cold Spring Harbor Perspectives in Medicine

Genetic Modifiers and Oligogenic Inheritance

Maria Kousi and Nicholas Katsanis

Cold Spring Harb Perspect Med 2015; doi: 10.1101/cshperspect.a017145

Subject Collection [Retinal Disorders: Genetic Approaches to Diagnosis and Treatment](#)

Trial by "Firsts": Clinical Trial Design and Regulatory Considerations in the Development and Approval of the First AAV Gene Therapy Product in the United States

Kathleen Z. Reape and Katherine A. High

Immunology of Retinitis Pigmentosa and Gene Therapy–Associated Uveitis

Paul Yang, Debarshi Mustafi and Kathryn L. Pepple

Developing New Vectors for Retinal Gene Therapy

Emilia A. Zin, Bilge E. Ozturk, Deniz Dalkara, et al.

Beyond the NEI-VFQ: Recent Experience in the Development and Utilization of Patient-Reported Outcomes for Inherited Retinal Diseases

Todd Durham, Judit Banhazi, Francesco Patalano, et al.

Electronic Retinal Prostheses

Daniel Palanker

Alternative RNA Splicing in the Retina: Insights and Perspectives

Casey J. Keuthan, Sadik Karma and Donald J. Zack

X-Linked Retinoschisis

Cristy A. Ku, Lisa W. Wei and Paul A. Sieving

A Systematic Review of Optogenetic Vision Restoration: History, Challenges, and New Inventions from Bench to Bedside

Antonia Stefanov and John G. Flannery

Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl

Jean Bennett and Albert M. Maguire

Therapeutic Gene Editing in Inherited Retinal Disorders

Jinjie Ling, Laura A. Jenny, Ashley Zhou, et al.

Cell-Based Therapies: Strategies for Regeneration

Marina Pavlou and Thomas A. Reh

The Importance of Natural History Studies in Inherited Retinal Diseases

Allison Ayala, Janet Cheetham, Todd Durham, et al.

Photoreceptor Cell Replacement Using Pluripotent Stem Cells: Current Knowledge and Remaining Questions

Christelle Monville, Olivier Goureau and Karim Ben M'Barek

iPSC-RPE in Retinal Degeneration: Recent Advancements and Future Perspectives

Tadao Maeda and Masayo Takahashi

Retinal Degeneration Animal Models in Bardet–Biedl Syndrome and Related Ciliopathies

Clarisse Delvallée and Hélène Dollfus

Mobility Testing and Other Performance-Based Assessments of Functional Vision in Patients with Inherited Retinal Disease

Daniel Chung, Colas Authié and Laure Blouin

For additional articles in this collection, see <http://perspectivesinmedicine.cshlp.org/cgi/collection/>